Early intervention with the multiple sclerosis treatment Teriflunomide delays the preliminary symptoms of the autoimmune disease, a new study reports. Those who took teriflunomide had a 72% lower risk of experiencing the initial symptoms of MS than those who took a placebo.
Early intervention with the multiple sclerosis treatment Teriflunomide delays the preliminary symptoms of the autoimmune disease, a new study reports. Those who took teriflunomide had a 72% lower risk of experiencing the initial symptoms of MS than those who took a placebo.
Share this Article
Recommended